| Symbol | JANX |
|---|---|
| Name | JANUX THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11099 N. TORREY PINES ROAD,SUITE 290, LA JOLLA, California, 92037, United States |
| Telephone | +1 858 750-4700 |
| Fax | — |
| — | |
| Website | https://www.januxrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001817713 |
| Description | Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. Additional info from NASDAQ: |
RA CAPITAL MANAGEMENT, L.P. 🟢 acquired 21.0K shares (1 derivative) of Janux Therapeutics, Inc. (JANX) at $13.66 Transaction Date: Jun 11, 2026 | Filing ID: 000631
Read moreSimson Jake 🟢 acquired 21.0K shares (1 derivative) of Janux Therapeutics, Inc. (JANX) at $13.66 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read moreKung Winston 🟢 acquired 21.0K shares (1 derivative) of Janux Therapeutics, Inc. (JANX) at $13.66 Transaction Date: Jun 11, 2026 | Filing ID: 000003
Read moreHernday Natasha 🟢 acquired 21.0K shares (1 derivative) of Janux Therapeutics, Inc. (JANX) at $13.66 Transaction Date: Jun 11, 2026 | Filing ID: 000004
Read moreDOBMEIER ERIC 🟢 acquired 21.0K shares (1 derivative) of Janux Therapeutics, Inc. (JANX) at $13.66 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read moreCAPPS VICKIE L 🟢 acquired 21.0K shares (1 derivative) of Janux Therapeutics, Inc. (JANX) at $13.66 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read moreBarrett Ronald W 🟢 acquired 21.0K shares (1 derivative) of Janux Therapeutics, Inc. (JANX) at $13.66 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read more(99% Neutral) JANUX THERAPEUTICS, INC. (JANX) Announces Regulatory Update
Read moreDoyle Janeen Noel 🔴 sold 4.1K shares of Janux Therapeutics, Inc. (JANX) at $14.03 Transaction Date: Jun 02, 2026 | Filing ID: 000005
Read more📋 Janeen Noel Doyle (Officer) plans to sell 4K shares of JANUX THERAPEUTICS, INC. (at $14.03 each, total $57K) Filed: Jun 02, 2026 | ID: 000004
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07545811 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Canc… | Phase1 | Prostate Cancer | Recruiting | 2026-04-15 | 2029-03-01 | ClinicalTrials.gov |
| NCT07291323 | Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. | Early_Phase1 | Autoimmune | Recruiting | 2026-02-16 | 2026-12-01 | ClinicalTrials.gov |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignanci… | Phase1 | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2023-04-19 | 2026-10-31 | ClinicalTrials.gov |
| NCT05519449 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Canc… | Phase1 | Prostate Cancer | Recruiting | 2022-09-15 | 2028-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| JANX008 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05783622 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX008 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT05783622 |
| Darolutamide | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT05519449 |
| JANX007 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT05519449 |
| JANX014 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07545811 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX014 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07545811 |
| JANX011 | Other | Phase EARLY_PHASE1 | Autoimmune | RECRUITING | NCT07291323 |
| JANX014 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07545811 |
| JANX014 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07545811 |
| JANX014 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07545811 |
| JANX014 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07545811 |
| JANX014 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07545811 |
| JANX014 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07545811 |
| JANX014 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07545811 |